Application of BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in Live Cells Tuesday, November 6, 2018View registration for sessions availablePresented by: Matthew RobersSenior Research Scientist and Group Leader, Promega Corporation and Kelvin LamSenior Director of Business Development, Reaction...
Tuesday, September 11, 2018 Time: 9am CDT/ 10am EDT/ 7am PDT 3pm London / 4pm Amsterdam-Paris Do you have questions about PCR? Our Technical Support Scientists Natascha Buter and Dr. Joliene Lindholm will be answering all your questions about nucleic acid amplification. ...
ABSTRACT This is a review of a research article that demonstrated the ability to assay cytochrome P450 activity in magnetic 3D hepatocytes using the P450-Glo™ CYP1A2 Induction and Inhibition Assay and CellTiter-Glo® 3D Luminescent Cell Viability Assay.Johanna Lee Promega CorporationPublication Date: August 2017;...
Abstract We used the NanoBRET™ assay from Promega to identify Myc-Max protein-protein interaction (PPI) inhibitors using the respective proteins tagged with NanoLuc® luciferase (NanoLuc®) and HaloTag® ligands. In addition to this, we used the Myc-Max NanoBiT® complementation assay to validate...
Circulating cell-free DNA (ccfDNA) can be used to monitor tumor burden and monitor disease progress. In this part 3 of 3 ccfDNA webinars, Dr. Gulley discusses variables important to isolating high-quality ccfDNA from plasma samples including anticoagulant, plasma volume and storage length and conditions.
